Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19
Jingyu Xiang, Mijia Lu, Min Shi, Xiaogang Cheng, Kristin A. Kwakwa, Jennifer L. Davis, Xinming Su, Suzanne J. Bakewell, Yuexiu Zhang, Francesca Fontana, Yalin Xu, Deborah J. Veis, John F. DiPersio, Lee Ratner, Ralph D. Sanderson, Alessandro Noseda, Shamim Mollah, Jiànróng Lǐ, Katherine N. Weilbaecher
Abstract
. In addition, HPSE blockade with Roneparstat significantly attenuated SARS-CoV-2 S1 protein-induced inflammatory cytokine release from human macrophages through disruption of NF-κB signaling. Together, this study provides a proof of principle for the use of Roneparstat as a dual-targeting therapy for COVID-19 to decrease viral infection and dampen the proinflammatory immune response mediated by macrophages.
Topics & Concepts
BiologyBlockadeCoronavirus disease 2019 (COVID-19)PathogenesisInflammation2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCoronavirusVirologyViral replicationVirusDiseaseMedicineReceptorPathologyGeneticsInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmune Response and Inflammation